Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review
BackgroundImmune-hemolytic anemia (IHA) is a rare immune-related adverse event (irAE) in cancer patients treated with immune-checkpoint inhibitors (ICIs). Although several cases of ICI-associated IHA have been reported, few attempts have been made to c…